Results 231 to 240 of about 58,085 (295)

Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease [PDF]

Tsung‐Hua Shen, Elizabeth S. Aby, David M. Vock, Joel F. Farley   +3 more
openalex   +1 more source

Dipeptidyl peptidase-4 inhibitor approaches.

Journal of diabetes, 2019
openaire   +1 more source

Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis

Jonggi Choi, Daniel Fulop, Vy H. Nguyen, Eric M. Przybyszewski, Jiunn Song, Allison J. Carroll, Megan Michta, Erik Almazan, Tracey G. Simon, Raymond T. Chung   +9 more
openalex   +1 more source

Discovery and characterization of novel bioactive peptides from marine secondary products [PDF]

, 2014
Falkenberg, Susan Skanderup
core  

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin

, 2013
Annalisa Capuano, L Sportiello, Maiorino MI, F Rossi, Dario Giugliano, K Esposito   +5 more
openalex   +1 more source

1,3-disubstituted benzimidazol-2-one derivative as a dipeptidyl peptidase-4 inhibitor

Pavlović Katarina Tomović, Oisaemi Uduagele Izevbekhai, Denitsa Yancheva, Anelia Ts Mavrova, Kameliya Anichina, Andrija; id_orcid 0000-0001-7724-0967 Šmelcerović   +5 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Dipeptidyl peptidase-4 inhibitors

Reactions Weekly, 2021
The dipeptidyl peptidase 4 (DPP-4) inhibitor has become a popular anti-diabetes medication since its introduction in 2006. They are small molecules that specifically bind to the catalytic domain of DPP-4, which consequently prevents the enzymatic inactivation of incretin hormones (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide)
Yoo Hyung Kim, Young Min Cho
openaire   +2 more sources

Dipeptidyl peptidase‐4 inhibitor treatment and the risk of bullous pemphigoid and skin‐related adverse events: A systematic review and meta‐analysis of randomized controlled trials

Diabetes/Metabolism Research Reviews, 2020
This meta‐analysis aimed to evaluate the risk of developing bullous pemphigoid (BP) and other skin‐related adverse events (AEs) in patients with type 2 diabetes (T2DM) undergoing dipeptidyl peptidase‐4 inhibitor (DPP‐4i) treatment in randomized ...
Wenjia Yang, X. Cai, Si-min Zhang, Xueyao Han, L. Ji   +4 more
semanticscholar   +1 more source

Dipeptidyl peptidase-4 inhibitor teneligliptin accelerates recovery from cisplatin-induced acute kidney injury by attenuating inflammation and promoting tubular regeneration.

Nephrology, Dialysis and Transplantation, 2019
Background Cisplatin is an effective chemotherapeutic agent. However, acute kidney injury (AKI) and subsequent kidney function decline limits its use. Dipeptidyl peptidase-4 (DPP-4) inhibitor has been reported to attenuate kidney injury in some in vivo ...
T. Iwakura, Zhibo Zhao, J. Marschner, S. K. Devarapu, H. Yasuda, H. Anders   +5 more
semanticscholar   +1 more source